ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Ke Jiang

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5123388522. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 3

Multimodal C9-66 CAR-T cell immunotherapy improves outcome in preclinical models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2025-337545 ↗
CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. Co-author DOI 10.1016/j.xcrm.2024.101692 ↗
Liquid biopsy in pancreatic cancer - Current perspective and future outlook. Co-author DOI 10.1016/j.bbcan.2023.188868 ↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Christopher Heeschen · 3 shared papers, 2023–2026 · strength 0.59
Jiajia Tang · 2 shared papers, 2023–2024 · strength 0.37
- Paper Liquid biopsy in pancreatic cancer - Current perspective and future outlook. DOI 10.1016/j.bbcan.2023.188868 ↗
- Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692 ↗
Yaru Zhao · 2 shared papers, 2023–2024 · strength 0.37
- Paper Liquid biopsy in pancreatic cancer - Current perspective and future outlook. DOI 10.1016/j.bbcan.2023.188868 ↗
- Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692 ↗
Miriam Roberto · 1 shared paper, 2026 · strength 0.22
- Paper Multimodal C9-66 CAR-T cell immunotherapy improves outcome in preclinical models of pancreatic cancer. DOI 10.1136/gutjnl-2025-337545 ↗
Elisabetta Fenocchio · 1 shared paper, 2024 · strength 0.15
- Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692 ↗
Da Fu · 1 shared paper, 2024 · strength 0.15
- Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692 ↗
Berina Šabanović · 1 shared paper, 2024 · strength 0.15
- Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692 ↗
Quan Zheng · 1 shared paper, 2024 · strength 0.15
- Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692 ↗
Chenlei Wen · 1 shared paper, 2024 · strength 0.15
- Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692 ↗
Baiyong Shen · 1 shared paper, 2024 · strength 0.15
- Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692 ↗
Qi Wang · 1 shared paper, 2024 · strength 0.15
- Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.